8-K: Current report filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported) March 26, 2003

EXEGENICS INC.
(Exact name of registrant as specified in its charter)

Delaware 00-26078 75-2402409
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)

2110 Research Row
Dallas, Texas 75235

(Address of principal executive
offices including zip code)

(214) 358-2000

(Registrant's telephone number,
including area code)


N.A.
(Former name or former address, if changed since last report)




Item 5. Other Events.

The previously disclosed conceptual agreement as to the termination of
the Master License Agreement between the Company and Bristol-Myers Squibb
Company has now been finalized. Under such termination agreement, the existing
Master License Agreement and related Sponsored Research Agreement and sublicense
agreements with Bristol-Myers Squibb Company were terminated, and the Company
was reimbursed for certain out-of-pocket expenses relating to the prosecution of
patents under such agreements. The Company has sent a termination notice to The
Washington State University Foundation ("WSURF") with respect to the Company's
related license from WSURF, which termination is to be effective as of June 30,
2003.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

EXEGENICS INC.
(Registrant)

Dated: April 11, 2003 By: /s/ Ronald L. Goode
-------------- ----------------------------------
Ronald L. Goode
Chairman, President and Chief
Executive Officer